Tavros Therapeutics develops a bi-directional synthetic lethality platform that combines functional and computational genomics to identify paired genetic interactions underlying tumor vulnerabilities. The platform is used to discover novel, de-risked, druggable targets and to clinically position existing and new molecules with biomarker-driven strategies. Tavros aims to improve patient outcomes, minimize toxicity, and speed development in defined patient subsets by accelerating target discovery and validation. The company has a strategic partnership with Zentalis Pharmaceuticals that has validated the platform and expanded its clinical impact. Tavros is also using its synthetic lethal relationship map to build a pipeline of category-defining small-molecule drug candidates. Led by CEO Eoin McDonnell, the company intends to use recent funding to continue developing its proprietary platform.

Total raised

$8M

Funding rounds

1

Latest round

Seed

Latest activity

Sep 2022